In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zentiva: Expanding in the CEE through M&A

Executive Summary

The formation of Zentiva through the merger of Léciva and Slovakofarma-the leading pharmaceutical players in the Czech and Slovak markets respectively-propels the merged entity into the top ranks of the CEE pharmaceutical industry and gives the company a firm base upon which to expand internationally. Yet unlike the majority of its peers who are looking to the West to drive future growth, Zentiva is looking East. The plan: to tap into the rapidly growing and less crowded CEE markets and lead the consolidation of the industry across the region.

You may also be interested in...



Eastern Europe: The Local Advantage

As the Eastern European and CIS markets expand, in some cases accelerated by EU enlargement, firms like Menarini--which in 1992 bought a strong presence in the area through its acquisition of Berlin-Chemie--are set to benefit from increasing in-licensing opportunities and growing sales. Local expertise is paramount in these markets: they may represent biggest growth opportunity in Europe, but most are still complex bureaucratically and politically, and protectionism remains rife in many states.

Eastern Europe: The Local Advantage

As the Eastern European and CIS markets expand, in some cases accelerated by EU enlargement, firms like Menarini--which in 1992 bought a strong presence in the area through its acquisition of Berlin-Chemie--are set to benefit from increasing in-licensing opportunities and growing sales. Local expertise is paramount in these markets: they may represent biggest growth opportunity in Europe, but most are still complex bureaucratically and politically, and protectionism remains rife in many states.

Pliva: Europe is Not Enough

Buying Sobel Holdings makes Croatia's Pliva one of the first eastern European companies to buy into the US market. It's doing so cleverly, leveraging future revenues from its biggest product, azithromycin, to fund the deal, and executing it through a tax-efficient Hungarian subsidiary.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel